USA
Analytical Standards
Controlled Research Environment
Research Product
Ipamorelin
1. Product Overview
pamorelin is a synthetic pentapeptide that has attracted scientific interest in research involving growth hormone secretagogue receptors (GHS-R), endocrine signaling pathways, peptide receptor interactions, and metabolic regulation. Ongoing studies continue to explore its role in growth hormone-related biological processes and peptide-mediated cellular communication. Ipamorelin is supplied as a lyophilized research peptide and undergoes analytical testing to verify identity, purity, and consistency.
Manufactured in a controlled research environment, this product is intended exclusively for laboratory and scientific research applications.
2. Specifications
| Product Name | Ipamorelin | Testing Method | HPLC |
|---|---|---|---|
| Synonym | Ipamorelin Acetate | Storage Condition | 2-8C |
| Format | Lyophilized Powder | Shelf Life | 24 Months |
| Content | 5 mg | Manufacturing Standard | GMP Standard Research Environment |
| Purity | >=99% HPLC | Country of Origin | USA |
| Appearance | White to Off White Lyophilized Powder | Intended Use | Research Use Only |
3. Research Summary
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue that has attracted significant scientific interest in studies involving endocrine signaling, growth hormone secretagogue receptors (GHS-R), peptide receptor interactions, metabolic regulation, and neuroendocrine communication pathways. Research has explored its interaction with biological systems involved in growth hormone-related signaling processes.
Preclinical and clinical investigations have examined the role of Ipamorelin in growth hormone regulatory mechanisms, peptide-mediated cellular communication, endocrine function, and metabolic research. Ongoing laboratory studies continue to evaluate its activity within growth hormone secretagogue pathways and broader endocrine signaling networks.
4. Scientific References
- Deghenghi R, Cananzi MM, Torsello A, et al. Growth hormone-releasing activity of Ipamorelin. European Journal of Endocrinology. 1998;139(1):89-95.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, a new growth hormone secretagogue with receptor selectivity. European Journal of Endocrinology. 1998;139(5):552-561.
- Svensson J, Lonn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 and relevance to growth hormone secretagogue research. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362-369.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides and secretagogues. European Journal of Endocrinology. 1997;136(5):445-460.
- Bowers CY. Growth hormone-releasing peptides and endocrine signaling research. Endocrine. 1998;8(1):7-11.
Disclaimer: This product is intended strictly for research use only. It is not intended for human consumption, clinical application, diagnostic procedures, therapeutic use, veterinary use, or household use. The information provided is for scientific and educational reference purposes only and should not be interpreted as medical advice, treatment guidance, or usage instructions. This product should be handled only by qualified professionals trained in laboratory practices. Purchasers and end users are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements governing the purchase, storage, handling, and use of research materials.
